Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Huang, PA
Boan Huang, Quakertown, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20110276349 | Publishing Templates Having Practice Defined Triggers - A healthcare management system is presented where the management system can include a data routing engine configured to route patient data to various authorized providers as a function of one or more trigger rules. The routing engine can operate as a web portal, through which clients of system can define medical form templates, where a template can include one or more triggering rules that cause further action to take place. When a patient interfaces to the web portal, the portal can render a medical form for the patient based on the template. As the patient interacts with the form, including entering their patient data, the routing engine can determine if any triggering criteria have been satisfied. If so, further actions can place including routing the data to authorized entities or providing notifications. | 11-10-2011 |
Chichi Huang, Radnor, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20090186020 | Melanocortin Receptor Binding Mimetibodies, Compositions, Methods and Uses - Melanocortin receptor binding mimetibody polypeptides are disclosed. Polynucleotides encoding these polypeptides, cells comprising these polynucleotides or expressing the mimetibodies, and methods of making and using the forgoing are also disclosed. | 07-23-2009 |
| 20110118144 | ENGINEERED PHAGE VECTORS FOR THE DESIGN AND THE GENERATION OF A HUMAN NON-ANTIBODY PEPTIDE OR PROTEIN PHAGE LIBRARY VIA FUSION TO PIX OF M13 PHAGE - The invention relates to a compositions and methods for generating and using pIX phage display libraries for producing non-antibody peptide or protein proteins or peptides using engineered hybrid phage vectors derived from pIX of M 13 phage. | 05-19-2011 |
Chichi Huang, Berwyn, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20080305130 | Marked Bovine Viral Diarrhea Virus Vaccines - The present invention is directed to a bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein the mutation in the NS3 domain results in a loss of recognition by a monoclonal antibody raised against wild-type NS3 but wherein viral RNA replication and the generation of infectious virus is retained. The present invention is useful, for example, to produce a marked bovine viral diarrhea virus vaccine or to differentiate between vaccinated and infected or unvaccinated animals. | 12-11-2008 |
| 20090220506 | HUMAN EPO MIMETIC HINGE CORE MIMETIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 09-03-2009 |
| 20100249032 | Human EPO Mimetic Hinge Core Mimetibodies, Compositions, Methods and Uses - The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 09-30-2010 |
| 20120021001 | MARKED BOVINE VIRAL DIARRHEA VIRUS VACCINES - The present invention is directed to a bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein the mutation in the NS3 domain results in a loss of recognition by a monoclonal antibody raised against wild-type NS3 but wherein viral RNA replication and the generation of infectious virus is retained. The present invention is useful, for example, to produce a marked bovine viral diarrhea virus vaccine or to differentiate between vaccinated and infected or unvaccinated animals. | 01-26-2012 |
Chong Huang, Paoli, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20090137783 | CNGH0010 Specific Polynucleotides, Polypeptides, Antibodies, Compositions, Methods and Uses - Novel polypeptides (CNGH0010) and antibodies, including specified portions or variants, specific for at least one such CNGH0010 polypeptide, variant, or fragment thereof, as well as nucleic acids encoding such CNGH0010 polypeptides and antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, are useful for therapeutic and diagnostic formulations, administration and devices. The aforesaid polypeptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-CNGH0010 antibodies. The CNGH0010 polypeptides and antibodies are used in modulating or treating at least one CNGH0010-related disease in a cell, tissue, organ, animal, or patient. Such diseases may include, but are not limited to, psoriasis, rheumatoid arthritis, emphysema, asthma, diabetes, autoimmune thyroiditis, inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, different types of dermatitis including allergic dermatitis, contact dermatitis, actinic keratosis, wound healing, scar formation, various renal diseases, various respiratory diseases, various diseases of reproductive organs, such as endometriosis, melanoma, squamous cell carcinoma, ovarian cancer, breast cancer, lung cancer, colon cancer, prostate cancer, renal cell carcinoma, Grave's diseases and other inflammatory and hyperproliferative diseases. | 05-28-2009 |
Chong Huang, Radnor, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20090270480 | Markers and Methods for Assessing and Treating Psoriasis and Related Disorders - A method for prognostic or diagnostic assessment of a skin-related disorder, such as psoriasis, in a subject correlates the presence, absence, and/or magnitude of a gene in a sample with a reference standard to determine the presence and/or severity of the disorder, and/or the response to treatment for the disorder. The method enables identification of the effectiveness of candidate therapies. | 10-29-2009 |
| 20100260675 | Oxytocin Receptor Antagonists and Their Use for the Treatment of Pulmonary Related Diseases - Methods of treating disorders related to Oxytocin Receptor activity utilize OXYTOCIN RECEPTOR antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, small molecule drugs, siRNA, shRNA, and DNAzymes. Disorders related to Oxytocin Receptor activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD. | 10-14-2010 |
Chris Huang, Radnor, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20100331209 | MARKERS AND METHODS FOR ASSESSING AND TREATING SEVERE OR PERSISTANT ASTHMA AND TNF RELATED DISORDERS - A method for assessment of the suitability of and/or effectiveness of a target therapy for a TNF-mediated-related disorder, such as severe or persistent asthma, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes corresponding to contacting the sample with a panel of nucleic acid segments consisting of at least a portion of at least one member from the group consisting of the nucleotide sequences corresponding to at least one of TNFRSF1A SNP rs4149581 (SEQ ID NO:1), TNFRSF1 B SNP rs3766730 (SEQ ID NO:2) or TNFRSFI B SNP rs590977 (SEQ ID NO:3) SNPs which results in a determination that one or more of said SNPs in a sample are in linkage disequilibrium (LD). The method enables identification of the effectiveness of target therapies prior to or after starting a patient on such therapies. | 12-30-2010 |
Gensheng Huang, Bethlehem, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20110204328 | NITRIDE BASED DEVICES INCLUDING A SYMMETRICAL QUANTUM WELL ACTIVE LAYER HAVING A CENTRAL LOW BANDGAP DELTA-LAYER - A symmetrical quantum well active layer provides enhanced internal quantum efficiency. The quantum well active layer includes an inner (central) layer and a pair of outer layers sandwiching the inner layer. The inner and outer layers have different thicknesses and bandgap characteristics. The outer layers are relatively thick and include a relatively low bandgap material, such as InGaN. The inner layer has a relatively lower bandgap material and is sufficiently thin to act as a quantum well delta layer, e.g., comprising approximately 6 Å or less of InN. Such a quantum well structure advantageously extends the emission wavelength into the yellow/red spectral regime, and enhances spontaneous emission. The multi-layer quantum well active layer is sandwiched by barrier layers of high bandgap materials, such as GaN. | 08-25-2011 |
| 20110240082 | THERMOELECTRIC MATERIALS BASED ON SINGLE CRYSTAL AlInN-GaN GROWN BY METALORGANIC VAPOR PHASE EPITAXY - The invention is a thermoelectric device fabricated by growing a single crystal AlInN semiconductor material on a substrate, and a method of fabricating same. In a preferred embodiment, the semiconductor material is AlInN grown on and lattice-matched to a GaN template on a sapphire substrate, and the growth is performed using metalorganic vapor phase epitaxy (MOVPE). | 10-06-2011 |
Jui Han Huang, Wallingford, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20110041190 | NOVEL CHIMERIC PROTEINS - Novel chimeric proteins are disclosed. The proteins comprise at least two portions. The first portion binds to a first cell and decreases the cell's ability to send a trans signal to a second cell; the second portion sends its own trans signal to the second cell. Methods for making and using these proteins in the treatment of cancer, viral infections, autoimmune and alloimmune diseases are also disclosed, as are pharmaceutical formulations comprising the novel chimeric proteins and genes. Either the proteins themselves or a genetic sequence encoding the protein can be administered. Other methods are also disclosed in which two molecular components result in decrement of a first trans signal from a first cell and the conferring of a second trans signal to a second cell. | 02-17-2011 |
Ke Huang, Philadelphia, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20080257414 | Method For Reduction Of Crude Oil Viscosity - The present invention relates to a method for reducing the viscosity and facilitating the flow of petroleum-based fluids. The method includes the step of applying an electric field of sufficient strength and for a sufficient time to the petroleum-based fluid to cause a reduction in viscosity of the fluid. | 10-23-2008 |
| 20100024783 | ELECTRIC-FIELD ASSISTED FUEL ATOMIZATION SYSTEM AND METHODS OF USE - An apparatus ( | 02-04-2010 |
| 20110048746 | AUTOMATIC REVERSIBLE TEMPERATURE RESPONSIVE VALVE AND FIRE SPRINKLER - A fire sprinkler including a generally tubular body having inlet and outlet ends is disclosed. The body defines a fluid flow passage extending between the inlet and the outlet such that the outlet is in fluid flow communication with the inlet. A magnetized member is disposed within the fluid flow passage and is movable between a first position wherein fluid flow communication between the outlet and the inlet is blocked and a second position wherein fluid flow communication between the outlet and the inlet is open. A temperature sensitive magnetic member is coupled to the body and has sufficient magnetic properties to attract the magnetized member below a predetermined temperature, thereby maintaining the magnetized member in the first position. The temperature sensitive magnetic member loses a sufficient percentage of its magnetic properties at and above the predetermined temperature, thereby allowing the magnetized member to move to the second position. | 03-03-2011 |
Kevin Huang, Export, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20100330450 | Tubular Solid Oxide Fuel Cells With Porous Metal Supports and Ceramic Interconnections - An intermediate temperature solid oxide fuel cell structure capable of operating at from 600° C. to 800° C. having a very thin porous hollow elongated metallic support tube having a thickness from 0.10 mm to 1.0 mm, preferably 0.10 mm to 0.35 mm, a porosity of from 25 vol. % to 50 vol. % and a tensile strength from 700 GPa to 900 GPa, which metallic tube supports a reduced thickness air electrode having a thickness from 0.010 mm to 0.2 mm, a solid oxide electrolyte, a cermet fuel electrode, a ceramic interconnection and an electrically conductive cell to cell contact layer. | 12-30-2010 |
| 20110033769 | Electrical Storage Device Including Oxide-ion Battery Cell Bank and Module Configurations - A rechargeable electrical storage device is disclosed, where one embodiment utilizes an anion (“A”) conducting electrolyte ( | 02-10-2011 |
| 20110038100 | Porous Carbon Oxide Nanocomposite Electrodes for High Energy Density Supercapacitors - A high energy density supercapacitor is provided by using nanocomposite electrodes having an electrically conductive carbon network having a surface area greater than 2,000 m | 02-17-2011 |
| 20110168572 | Composite Mixed Carbonate Ion and Electron Conducting Membranes and Reactant Gas Assisted Chemical Reactors for CO2 Separation and Capture - The present disclosure relates to a system for carbon dioxide seperation and capture. The system includes a porous metal membrane comprising Ni, Ag, or combinations thereof and having molten carbonate within the pores. A CO | 07-14-2011 |
| 20110256448 | MOLTEN SALT-CONTAINING METAL ELECTRODE FOR RECHARGEABLE OXIDE-ION BATTERY CELLS OPERATING BELOW 800?C - A rechargeable oxide-ion battery cell | 10-20-2011 |
| 20120014852 | Membranes and Reactors for CO2 Separation - The present disclosure relates to a system for carbon dioxide separation. The system includes a conducting membrane having two phases. The first phase is a solid oxide porous substrate. The second phase is molten carbonate. The second phase is positioned within the solid oxide porous substrate of the first phase. The system also includes a H | 01-19-2012 |
| 20120034520 | SELF-SEALED METAL ELECTRODE FOR RECHARGEABLE OXIDE-ION BATTERY CELLS - The outer surface of a metal electrode | 02-09-2012 |
| 20120058396 | OXIDATION-RESISTANT METAL SUPPORTED RECHARGEABLE OXIDE-ION BATTERY CELLS AND METHODS TO PRODUCE THE SAME - The invention describes the application of oxidation-resistant metal (preferably, stainless steel) | 03-08-2012 |
Liquan Huang, Havertown, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20080307536 | Voltage-Gated, Ph-Sensitive Anion Channel And Its Novel Splice Variant Involved In Taste Sensation - The invention provides a novel splice-variant of the ClC-4 protein, termed ClC-4A. ClC-4A is expressed in taste bud cells and is involved in sour taste perception. The invention provides ClC-4A polynucleotides and ClC-4A polypeptides, vectors, host cells and ClC-4A specific antibodies as well as designing high potency taste stimuli, determining taste preferences in animals, developing breed-specific foods, and modifying the taste of foods and medications. | 12-11-2008 |
Liying Huang, State College, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20120105471 | Systems and Methods for Data Aggregation and Prioritization - Computer-enabled systems and methods aggregate data related to a particular subject or field and present the data in a simplified display. The data is divided into predetermined categories, which are graphically displayed in a predetermined arrangement. Systems and methods differentiate and visually display critical data abnormalities separately from non-critical data. The systems and methods enable an observer to identify the critical deviations or anomalies of data with respect to a predetermined base line by an intuitive visual display of all of the data from any sized data universe on a single screen. The data is indexed at multiple display levels such as a stack of one patient's data, a stack of all patient data for the universe of patients of a single practitioner, or a group of practitioners of any size. A portion of the display preferably may be selected and expanded to show only that portion in greater detail. | 05-03-2012 |
Pearl S. Huang, Lansdale, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20100280987 | METHODS AND GENE EXPRESSION SIGNATURE FOR ASSESSING RAS PATHWAY ACTIVITY - Methods, biomarkers, and expression signatures are disclosed for assessing the regulation status of RAS pathway signaling in a cell sample or subject. More specifically, several aspects of the invention provide a set of genes which can be used as biomarkers and gene signatures for evaluating RAS pathway deregulation status in a sample; classifying a cell sample as having a deregulated or regulated RAS signaling pathway; determining whether an agent modulates the RAS signaling pathway in sample; predicting response of a subject to an agent that modulates the RAS signaling pathway; assigning treatment to a subject; and evaluating the pharmacodynamic effects of cancer therapies designed to regulate RAS pathway signaling. | 11-04-2010 |
Philip Lin Huang, Maple Glen, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20090061031 | Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus - The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPARγ2, LPL and αP2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues. | 03-05-2009 |
| 20110142973 | Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus - The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPARγ2, LPL and αP2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues. | 06-16-2011 |
Qihong Huang, Philadelphia, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20100196357 | Microrna modulators and method for identifying and using the same - The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease. | 08-05-2010 |
| 20100317628 | MicroRNA Modulators and Method for Identifying and Using the Same - The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease. | 12-16-2010 |
| 20110064828 | TREATMENT OF METASTATIC TUMORS AND OTHER CONDITIONS - The present invention generally relates to pharmacology and, in particular, to the treatment of tumors and other conditions. In some aspects, the invention is directed to the treatment of subjects having tumors or cancers that are metastatic. Surprisingly, it has been found that certain compositions comprising oxidized glutathione-based compounds are able to effectively treat such cancers by inhibiting cell migration and/or invasion processes, and thus, inhibiting tumor cell metastases. Without being bound by any theory, it is believed that such compositions are effective since the compositions are able to suppress the activation of critical signaling pathways within cells that are used for cell migration, such as the ErbB2 and/or phosphoinositide-3 kinase (PI3K) pathways, including the downstream RhoA and AKT pathways. Such pathways are regulated by ERp5, which is a protein disulfide isomerase regulated using certain redox pathways, and those redox pathways are unusually sensitive to treatment using oxidized glutathione-based compounds. Thus, the composition of the instant invention, in some embodiments, are surprisingly effective at preventing tumor metastases. While other references have disclosed the treatment of cancers using oxidized glutathione-based compounds, no reference has suggested that signaling pathways used for cell migration, invasion and metastasis, such as the ErbB2, PI3K, RhoA, and AKT pathways, are highly susceptible to treatment by altering the redox state of the cell, e.g., by oxidized glutathione-based compounds. Accordingly, the use of such compositions to treat tumor metastases is surprising and could not be predicted given the teachings of the prior art. | 03-17-2011 |
| 20120010177 | MicroRNA Modulators and Method for Identifying And Using The Same - The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease. | 01-12-2012 |
Shaei Y. Huang, Jeffersonville, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20080280967 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels - Imido and amido substituted acylhydroxamic acids which reduce the levels of TNFα and inhibit phosphodiesterase in a mammal. A typical embodiment is (3-(1,3-dioxoisoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propanoylamino)propanoate. | 11-13-2008 |
Shaei Y. Huang, Lansdale, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20080280902 | Inhibitors of Checkpoint Kinases - The instant invention provides for compounds which comprise substituted quinolinones that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer. | 11-13-2008 |
| 20090258852 | Inhibitors of Checkpoint Kinases - The instant invention provides for compounds which comprise benzoisoquinolinones and aza derivatives that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer. | 10-15-2009 |
| 20110124661 | OXAZOLOBENZIMIDAZOLE DERIVATIVES - The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved. | 05-26-2011 |
Tony J. Huang, State College, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20110013287 | Tunable Liquid Gradient Refractive Index Lens Device - A lens device includes a substrate having a channel and a first fluid flow path and a second fluid flow path. The first and second fluid flow paths at least partially in communication with the channel. A light emitting device is positioned adjacent to the channel. At least one first fluid source is in communication with the first fluid path such that a first fluid is moveable along the first fluid path and at least one second fluid source in communication with the second fluid path such that a second fluid is moveable along the second fluid path. The first second fluid paths are configured so the first fluid and second fluid move through the channel to define an adjustable liquid gradient refractive index distribution in the channel. Adjustment of the liquid gradient refractive index distribution permits a change of liquid lens focal distance or an angular adjustment of light emitted by the light emitting device. | 01-20-2011 |
Tony Jun Huang, State College, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20090066936 | THREE-DIMENSIONAL (3D) HYDRODYNAMIC FOCUSING USING A MICROFLUIDIC DEVICE - A microfluidic device comprises inlets for a sample flow and an out-of-plane focusing sheath flow, and a curved channel section configured to receive the sample flow and out-of-plane focusing sheath and to provide hydrodynamic focusing of the sample flow in an out-of-plane direction, the out-of-plane direction being normal to a plane including the curved channel. | 03-12-2009 |
| 20100139377 | PARTICLE FOCUSING WITHIN A MICROFLUIDIC DEVICE USING SURFACE ACOUSTIC WAVES - Examples of the present invention include apparatus and methods for particle focusing, for particles within a fluid sample. An example apparatus, which may be a microfluidic device, comprises a substrate, a channel receiving the fluid sample, and at least one surface acoustic wave (SAW) generator. The SAW generator may comprise electrodes supported by the substrate. In some examples, the channel has a particle focusing region located near a region of the substrate surface in which a SAW is generated. Particles are concentrated within one or more particle focus regions of the sample flow (the particle focus regions being appreciably narrower than the channel dimensions) by the effects of the SAW. As an example, a pair of SAW generators can be used to generate a standing surface acoustic wave (SSAW) that is used for particle focusing. | 06-10-2010 |
Xiaolei Huang, Bethlehem, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20090148013 | System and Methods for Generating Three-Dimensional Images From Two-Dimensional Bioluminescence Images and Visualizing Tumor Shapes and Locations - A system and methods for generating 3D images ( | 06-11-2009 |
Xiaoming Huang, State College, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20090042091 | Supported catalyst layers for direct oxidation fuel cells - A method of fabricating a supported catalyst layer for use in a fuel cell electrode, comprises sequential steps of: combining a fluid ink including a supported catalyst comprising at least one precious metal or alloy supported on particles of a support material, and a solution of at least one ionomeric polymer material, with at least one pore-forming material; forming a layer of the combined ink on a surface of a sheet of support material; hot pressing the layer; and treating the hot-pressed layer to remove pore-forming material to form a supported catalyst layer. | 02-12-2009 |
| 20110200914 | HIGH POWER DIRECT OXIDATION FUEL CELL - A high power density direct oxidation fuel cell (DOFC) with comprising an anode electrode with a microporous layer (MPL) configured to alleviate cathode dryout and thus reduce electrode resistance in the cathode that interfaces with a hydrocarbon membrane. The MPL is configured to alleviate cathode dryout by comprising a fluoropolymer and an electrically conductive material, wherein the MPL is loaded with fluoropolymer in the range from about 10 to about 25 wt. %. | 08-18-2011 |
Xinghui Huang, Pittsburgh, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20090154004 | Servo architecture for high areal density data storage - A track accessing mechanism includes a track accessing arm actuable by a primary actuation device for accessing concentric data tracks on a storage medium and at least one slider attached to the track accessing arm. The at least one slider includes a servo head configured to read positional information from a plurality of continuous, concentric rings radially spaced apart from each other on a storage medium and a data head configured to read and write user data to the least one concentric data track. At least a portion of each ring includes servo information. The at least one data track is positioned between each continuous, concentric ring on the storage medium. | 06-18-2009 |
Yifang Huang, City Lansdale, PA US
Yifang Huang, Lansdale, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20110105562 | ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS - The present invention is directed to novel alkynyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1. | 05-05-2011 |
| 20110224209 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-1 (DPP-1) - The present invention is directed to 4,4-di-substituted piperidine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1. | 09-15-2011 |